Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study

Nile Therapeutics, a company focused on the development of novel therapeutics for heart failure patients, announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure.
Forbes